Core Viewpoint - The stock of Peijia Medical (02565) has risen over 7%, reaching a new high of HKD 38.66, following the release of its interim performance report, indicating positive market sentiment towards the company's future prospects [1] Financial Performance - The company reported other net income of RMB 178,000 and research and development expenses of RMB 26.294 million, with a loss per share of RMB 0.25 [1] Product Development and Commercialization - Peijia Medical's NDA for PB-119 has been accepted by the National Medical Products Administration, with expectations for commercialization in China soon [1] - The company anticipates that post-listing, it will incur costs related to its operations as a public company, with financial performance expected to fluctuate based on the development status of candidate drugs, potential collaboration timelines, and regulatory approval schedules [1] Strategic Focus - The company has successfully established a pipeline matrix covering six investigational drugs targeting chronic diseases [1] - Peijia Medical's core strategy focuses on the treatment of metabolic diseases and their complications, with multiple candidate drugs showing dual value potential as "first-in-class" (FIC) and "best-in-class" (BIC), laying a solid foundation for future market competitiveness [1]
港股异动 | 派格生物医药-B(02565)涨超7%再创新高 PB-119上市注册申请已获受理 国内商业化即将落地